Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions By Ogkologos - June 23, 2026 242 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer May 10, 2018 Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress April 30, 2020 March is Multiple Myeloma Action Month March 29, 2022 Is That New Lump or Bump a Sarcoma? February 28, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tepotinib New Safety Signal for Use of Ibrutinib in Combination with Rituximab... Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... How to Be Brave When Your Parent Has Cancer: A Kid’s...
